Zimmer once again gives European regulators more time to rule on Biomet deal

Zimmer ($ZMH) agreed to give European regulators more information and time to inspect its planned acquisition of fellow orthopedics company Biomet for $13.35 billion. The European Commission was scheduled to rule on the transaction by March 11. Now the deadline has been extended by a "limited number of days," Zimmer says. This is not the first extension. Originally, a decision was expected by Feb. 16. U.S. regulators must also approve the deal. In spite of the extension for the Europeans, Zimmer still expects the deal to close in the first quarter of 2015. Article (sub. req.)

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.